[ @entity16332 and XXXX significantly improved the prognosis of early-to-mid stage @entity1956 related @entity879 ].

@entity1 @entity97 @entity2353 @entity16332 @entity3182 @entity1956 @entity879 @entity17705 @entity1575 @entity99
OBJECTIVE: To clinically study the antiviral effects of @entity16332 and @entity17705 on @entity1 with early-to-mid stage @entity1956 related @entity879 ( @entity97 -ACLF). METHODS; A prospective, randomized, open and parallel controlled clinical trial was designed to observe the antiviral effects of @entity2353 analogues on @entity1 with early-to-mid stage @entity97 -ACLF. Three groups were set for controlled study, i. e. basic treatment group, @entity16332 plus basic treatment group and @entity17705 plus basic treatment group. RESULTS: One month after treatment, the improvement rates of @entity16332 group and @entity17705 group were 58.85% and 59.15% respectively, significantly higher than that of basic treatment group which was 34.84% (Chi(2) = 9.8323, P = 0.043). By the end of six months, the cumulative survival rates of @entity1 with the antiviral treatments, i.e., @entity16332 , @entity17705 , were 65.8%, 60.1%, significantly higher than that (42%) without the antiviral treatment (P = 0.045, P = 0.04 respectively). The cumulative survival rate in @entity1 with a MELD score < 30 was higher than that with a MELD score over 30 (Chi(2) = 3.920, P = 0.048). For the @entity1 with pretreatment @entity97 DNA > or = 10(7), the cumulative survival rate in @entity1 with @entity17705 treatments group was higher than that of @entity1 in basic treatment group (Chi(2) = 5. 014 P= 0.025). According to the Ordinal Regression analysis, antiviral therapy by using either @entity16332 or entecavia could significantly increase the improvement rate of @entity1 with early-to-mid stage @entity97 -ACLF. But severe complications, including @entity3182 , electrolyte imbalance and @entity99 , medical history of @entity1575 , and pretreatment @entity97 DNA > or = 10(7) had significant impacts on prognosis of this group patients. CONCLUSIONS: Antiviral therapy by using either @entity16332 or entecavia could significantly increase the survival rate of @entity1 with early-to-mid stage @entity97 -ACLF.
